Machine learning models classify the likelihood of developing Alzheimer's.

Published Date: 05 Apr 2023

A new study suggests that once adults reach age 65, the cutoff age for Alzheimer's disease onset, the extent of their genetic risk may outweigh age as a predictor of whether they will experience the fatal brain disorder.

Read Full News

Latest News

Brain-Penetrant Molecule GT-02287 Demonstrates Reversal of Glucosylsphinogosine in Parkinson Disease Marco Meglio

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

Remyelinating Agent PIPE-307 Falls Short in Phase 2 Trial of Relapsing Multiple Sclerosis Marco Meglio

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

This Week on NeurologyLive® — December 22, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

CAPN2-Targeting Agent AMX0114 Shows Safe Profile in Phase 1 LUMINA Trial of ALS Marco Meglio

New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.

NeurologyLive® Brain Games: December 21, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!

Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook Marco Meglio

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

Todays Updates

Adults with Developmental and Epileptic Encephalopathies in the Precision Treatment Era Danielle Andrade, MD, MSc

Explore the evolving landscape of developmental and epileptic encephalopathies in adults, highlighting precision therapies and the need for accurate diagnoses.

What’s All the Buzz? Trending Topics and Phrases of Neurology in 2025 Marco Meglio

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Todays Updates

Adults with Developmental and Epileptic Encephalopathies in the Precision Treatment Era Danielle Andrade, MD, MSc

Explore the evolving landscape of developmental and epileptic encephalopathies in adults, highlighting precision therapies and the need for accurate diagnoses.

What’s All the Buzz? Trending Topics and Phrases of Neurology in 2025 Marco Meglio

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Latest News

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

Here's some of what is coming soon to NeurologyLive® this week.

New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

News All Time

Understanding the Therapeutic Potential and Promising Early-Stage Data on Azetukalner for Focal Onset Seizures Marco Meglio

Christopher Kenney, MD, FAAN, chief medical officer at Xenon Pharmaceuticals, reviews encouraging long-term data behind azetukalner, a first-in-class Kv7 channel opener, as a potential treatment for focal onset seizures.

How Social Robotics and Embodied AI Could Reshape Neurology Care Neal K. Shah

Neal K. Shah talked about how social robots could support emotional well-being in patients with neurologic conditions by reducing loneliness and promoting engagement in health-related activities.

NeurologyLive® Brain Games: December 14, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!

This Week on NeurologyLive® — December 15, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Refining Prognosis and Treatment in Post–Resuscitation Epilepsy Care Andrea Rossetti, MD, Louie Pasculli

Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.

Beyond Dravet and LGS: Elizabeth Thiele, MD, PhD, on New Data for Epidiolex in DEEs Marco Meglio

Elizabeth Thiele, MD, PhD, director of the Pediatric Epilepsy Program at Massachusetts General Hospital, discusses new data on Epidiolex use in DEEs beyond Dravet, LGS, and TSC.

NeurologyLive® Friday 5 — December 12, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 12, 2025.

Investigational TRPM8 Antagonist Elismetrep Achieves Positive Phase 2b Data in Acute Migraine Isabella Ciccone, MPH

New data from a phase 2b trial showed that elismetrep showed favorable efficacy and safety outcomes compared with placebo, supporting its continued development as a potential acute migraine therapy.

Episode 156: Building Better Mood and Behavior Care for Parkinson Disease Marco Meglio, Sneha Mantri, MD, MS

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]

FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis Isabella Ciccone, MPH

Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.

FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS Isabella Ciccone, MPH

The phase 3 study aims to confirm findings from the HEALEY ALS platform trial in patients with early-stage rapidly progressive ALS, which suggested potential benefits of pridopidine across multiple domains.

Cell Therapy Deramiocel Meets Primary End Point in Phase 3 DMD Cardiomyopathy Trial Isabella Ciccone, MPH

Capricor Therapeutics anticipates that detailed phase 3 data from the HOPE-3 study will be submitted for presentation at a future scientific meeting and for publication in a peer-reviewed journal.

EPX-100 Shows Promising Seizure Reduction in Ongoing Open-Label Extension Louie Pasculli

New data from the open-label extension of Harmony Biosciences’ Phase 3 ARGUS trial show that EPX-100 (clemizole) achieved a median 50% reduction in countable motor seizures in patients with Dravet Syndrome.

Michael Sperling, MD, on AES Lifetime Achievement Award, Evolution in Epilepsy Care Michael R. Sperling, MD, Louie Pasculli

Michael Sperling, MD, Baldwin Keyes Professor of Neurology at Vice Chair for Research at the Sidney Kimmel Medical College, spoke about the significance of receiving the Founders Award and the current state of epilepsy.

Z-Rostudirsen Meets Primary End Point in Phase 1/2 DELIVER Trial for Duchenne Muscular Dystrophy Isabella Ciccone, MPH

Long-term treatment with z-rostudirsen over 24 months showed sustained functional improvements across all end points in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

AES Poster Showcases Feasibility of Mobile App to Track Daily Self-Reporting Epilepsy Outcomes Isabella Ciccone, MPH

A new study presented at AES 2025 reported that a cognitive-behavioral intervention via mobile application for patients with epilepsy can reliably capture daily self-reported outcomes.

Recommended News For You

Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma

Despite reports of hundreds of cancer cases, carcinogens have been discovered at nuclear missile sites in Montana.

Accurately identified high-grade prostate cancer through urine testing.

Tafasitamab-Based Combination Boosts PFS in Relapsed/Refractory Follicular Lymphoma

Financial hardship common in patients with cancer

Glioblastoma cells can 'unstick' from their neighbors to become more deadly

Early breast cancer detection may be possible with a wearable ultrasound scanner.

Recommended Articles For You

A Novel Gemcitabine-Releasing Intravesical System for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer 

Radiation Oncology: Integrating AI, Theranostics, and Adaptive Therapies for Personalized Cancer Care 

Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer 

Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

AI tool identifies women at high risk of interval breast cancer

2.

An Eye Surgeon's Unexpected Discovery of the "Before and After".

3.

Researchers investigate risk of developing multiple primary cancers after surviving bowel cancer

4.

Chronic pain and poor sleep are troublesome bed partners.

5.

Childhood cancer survivors face new health problems later in life, study shows

1.

Unlocking the Potential of Pirtobrutinib: A New Frontier in Cancer Treatment

2.

How EPCORITAMAB is Revolutionizing the Treatment of Cancer

3.

Asymptomatic Thrombocytopenia: Unraveling the Enigma of Low Platelet Counts Without Symptoms

4.

The Benefits and Risks of Cervical Conization

5.

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

2.

Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men

3.

Navigating the Complexities of Ph Negative ALL - Part XIV

4.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

5.

Thromboprophylaxis In Medical Settings- An Update

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot